CymaBay down on Phase IIb NASH miss

CymaBay fell $5.04 (45%) to $6.05 on Tuesday after the company announced seladelpar missed the primary endpoint in a Phase IIb trial to treat NASH.

In 181 patients with biopsy-confirmed NASH, CymaBay Therapeutics Inc. (NASDAQ:CBAY) said the peroxisome proliferation activated receptor δ (PPARδ) agonist missed the trial's primary endpoint of change in liver fat content from baseline to 12 weeks as measured by MRI proton density fat fraction (MRI-PDFF). ...